UY28038A1 - Nuevas formulaciones de liberación propongada inyectables - Google Patents

Nuevas formulaciones de liberación propongada inyectables

Info

Publication number
UY28038A1
UY28038A1 UY28038A UY28038A UY28038A1 UY 28038 A1 UY28038 A1 UY 28038A1 UY 28038 A UY28038 A UY 28038A UY 28038 A UY28038 A UY 28038A UY 28038 A1 UY28038 A1 UY 28038A1
Authority
UY
Uruguay
Prior art keywords
release formulations
new injectable
proposed release
injectable
proposed
Prior art date
Application number
UY28038A
Other languages
English (en)
Spanish (es)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28038A1 publication Critical patent/UY28038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
UY28038A 2002-10-25 2003-10-24 Nuevas formulaciones de liberación propongada inyectables UY28038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
UY28038A1 true UY28038A1 (es) 2004-05-31

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28038A UY28038A1 (es) 2002-10-25 2003-10-24 Nuevas formulaciones de liberación propongada inyectables

Country Status (20)

Country Link
US (1) US20040138237A1 (https=)
EP (1) EP1575616A2 (https=)
JP (1) JP2006514923A (https=)
KR (1) KR20050055781A (https=)
CN (1) CN1849110A (https=)
AR (1) AR041722A1 (https=)
AU (1) AU2003267788A1 (https=)
BR (1) BR0315568A (https=)
CA (1) CA2503076A1 (https=)
MX (1) MXPA05002561A (https=)
NL (1) NL1024590C2 (https=)
NO (1) NO20052463L (https=)
PA (1) PA8586201A1 (https=)
PE (1) PE20040499A1 (https=)
PL (1) PL377679A1 (https=)
RU (1) RU2310450C2 (https=)
TW (1) TW200423941A (https=)
UY (1) UY28038A1 (https=)
WO (1) WO2004037289A2 (https=)
ZA (1) ZA200501921B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
AU2005287175B2 (en) * 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20110144202A1 (en) * 2008-06-16 2011-06-16 Uwe Marx Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
ATE234097T1 (de) * 1999-05-27 2003-03-15 Pfizer Prod Inc Ziprasidonsuspension
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
JP2006514923A (ja) 2006-05-18
KR20050055781A (ko) 2005-06-13
NO20052463L (no) 2005-05-23
CN1849110A (zh) 2006-10-18
WO2004037289A3 (en) 2005-12-01
ZA200501921B (en) 2006-10-25
WO2004037289A2 (en) 2004-05-06
CA2503076A1 (en) 2004-05-06
BR0315568A (pt) 2005-08-23
RU2005112207A (ru) 2005-09-10
MXPA05002561A (es) 2005-05-05
PE20040499A1 (es) 2004-08-18
PA8586201A1 (es) 2004-09-16
PL377679A1 (pl) 2006-02-06
AR041722A1 (es) 2005-05-26
NL1024590A1 (nl) 2004-04-27
EP1575616A2 (en) 2005-09-21
TW200423941A (en) 2004-11-16
RU2310450C2 (ru) 2007-11-20
US20040138237A1 (en) 2004-07-15
NL1024590C2 (nl) 2005-05-23
AU2003267788A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
UY28038A1 (es) Nuevas formulaciones de liberación propongada inyectables
BR0312635A (pt) Composições de implante farmacêutico lipofìlico não polimérico para uso intraocular
BR0307066A (pt) Dispositivo médico resistente a infecção
BRPI0409516A (pt) composição, uso de uma composição e processo de melhora da penetração de um ativo farmacêutico
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
AR054227A1 (es) Composicion de principios activos
CO5690539A2 (es) Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
CL2007001205A1 (es) Compuestos derivados de n-fenil-3-tio-4-fenil-azetedin-2-ona; procedimiento de preparacion; composicion farmaceutica; combinacion; uso en el tratamiento de una condicion hiperlipidemica, ateroesclerosis, alzheimer y tumores asociados a colesterol
BR0208776B1 (pt) uso de etoxilatos de álcool graxo como promotores de penetração, bem como composições para tratamento de plantas.
CR7995A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas correspondiente metodo de produccion , medicamentos que lo contienen y uso de los mismos
DE602004019331D1 (de) Mit malonsäuresalzen stabilisierte terpenoid-duftkomponenten
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
PE20020909A1 (es) Una combinacion que comprende combretastatina y agentes anticancerigenos
TW200509863A (en) Irradiation device for medical use
GT200300064A (es) Formulacion farmaceutica que comprende melatonina
AR051385A1 (es) Agentes de curtido a base de isocianato
AR053571A1 (es) Prevencion de infeccion por vih
MXPA06012566A (es) Tratamiento de enfermedades infecciosas.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
GT200500349A (es) Formulaciones de benzoxazoles substituidos
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126